Evotec SE EVO
NASDAQ EVO
$1.81 -0.01 (-0.55%)
At close: Sep 9, 2026 · 4:00 PM EDT

Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025)

Evotec SE's (EVO) quarterly Net Income towards Common Stockholders came in at -$33.3 million in Q4 2025, up 60.83% year-over-year from -$20.7 million in Q4 2024, and up 33.56% quarter-over-quarter from -$50.1 million in Q3 2025.

Analysis

Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025) Analysis & Trends

Evotec SE has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$33.3 million for Q4 2025.

  • In Q4 2025, Net Income towards Common Stockholders rose 60.83% year-over-year to -$33.3 million; the TTM figure through Dec 2025 stood at -$144.4 million (up 50.69% YoY), while the FY2025 annual figure was -$79.1 million, up 61.91% from the prior year.
  • Net Income towards Common Stockholders came in at -$33.3 million for Q4 2025 at Evotec SE, up from -$50.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $158.3 million in Q3 2021 to a low of -$112.6 million in Q2 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$14.7 million, with a median of -$32.4 million recorded in 2025.
  • The largest YoY upside for Net Income towards Common Stockholders was 9714.16% in 2021 against a maximum downside of 7140.17% in 2021.
  • Over 5 years, Net Income towards Common Stockholders stood at -$36.0 million in 2021, then jumped by 177.07% to $27.8 million in 2022, then tumbled by 223.75% to -$34.3 million in 2023, then sank by 147.3% to -$84.9 million in 2024, then surged by 60.83% to -$33.3 million in 2025.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$33.3 million in Q4 2025, -$50.1 million in Q3 2025, and -$31.4 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Iqvia Holdings 44.06 Bn 42.11 Bn 1.44 Bn 241.00 Mn
2 Medpace Holdings 16.50 Bn 16.00 Bn 201.64 Mn 121.36 Mn
3 Charles River Laboratories International 13.77 Bn 13.62 Bn 452.07 Mn -760,000.00
4 Icon 12.62 Bn 11.69 Bn 479.29 Mn 198.40 Mn
5 Fortrea Holdings 1.68 Bn 1.51 Bn 139.20 Mn -13.20 Mn
6 Evotec SE 661.34 Mn 235.46 Mn - -
7 Ginkgo Bioworks Holdings 442.79 Mn 358.26 Mn 18.44 Mn -46.71 Mn
8 Champions Oncology 72.49 Mn 72.62 Mn 7.03 Mn -667,000.00
9 MindWalk Holdings 61.66 Mn 53.38 Mn 1.82 Mn -2.50 Mn
10 VivoSim Labs 1.47 Mn 1.47 Mn - -2.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -33.27 Mn
Sep 30, 2025 -50.07 Mn
Jun 30, 2025 -31.44 Mn
Mar 31, 2025 -29.58 Mn
Dec 31, 2024 -84.93 Mn
Sep 30, 2024 -59.43 Mn
Jun 30, 2024 -112.65 Mn
Mar 31, 2024 -35.73 Mn
Dec 31, 2023 -34.34 Mn
Jun 30, 2023 -13.89 Mn
Dec 31, 2022 27.75 Mn
Sep 30, 2022 47.67 Mn
Jun 30, 2022 -29.81 Mn
Mar 31, 2022 -82.20 Mn
Dec 31, 2021 -36.01 Mn
Sep 30, 2021 158.34 Mn
Jun 30, 2021 72.27 Mn
Mar 31, 2021 63.57 Mn
Dec 31, 2020 511,492.35
Sep 30, 2020 -1.65 Mn